SEC Form 10-Q filed by Amneal Pharmaceuticals Inc.
$AMRX
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/6/2024 | $9.00 | Underweight → Neutral | JP Morgan |
JP Morgan upgraded Amneal Pharmaceuticals from Underweight to Neutral and set a new price target of $9.00
RBC Capital Mkts resumed coverage of Amneal Pharmaceuticals with a rating of Sector Perform and set a new price target of $5.00
The Goldman Sachs Group upgraded Amneal Pharmaceuticals from Sell to Buy and set a new price target of $6.50 from $4.00 previously
8-K/A - Amneal Pharmaceuticals, Inc. (0001723128) (Filer)
10-Q - Amneal Pharmaceuticals, Inc. (0001723128) (Filer)
8-K - Amneal Pharmaceuticals, Inc. (0001723128) (Filer)
4 - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)
4 - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)
4 - Amneal Pharmaceuticals, Inc. (0001723128) (Issuer)
SC 13G/A - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)
SC 13D/A - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)
SC 13D/A - Amneal Pharmaceuticals, Inc. (0001723128) (Subject)
- Celebrating Amneal's recent listing on the Nasdaq Stock Exchange Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), a global pharmaceutical company, today announced that Chirag and Chintu Patel, Co-founders and Co-Chief Executive Officers, will ring the Nasdaq closing bell on Tuesday, April 2, 2024. "As entrepreneurs who founded Amneal in 2002, we are pleased to join the esteemed roster of Nasdaq-listed companies. Today Amneal is a growing global pharmaceutical leader with a diverse portfolio of essential medicines that help make healthy possible. Our focus on patient access and affordability allows us to improve countless lives, and our commitment to innovation a
Ms. Autor will further HIC's role as a sought-after advisor to global life sciences organizations Healthcare Innovation Catalysts, Inc. (HIC), a leading provider of regulatory affairs, clinical advisory, quality, compliance, federal partnership, and strategic advisory services to global life sciences organizations, announced today that Deborah M. Autor, former Deputy Commissioner of the U.S. Food and Drug Administration (FDA), has joined the firm as its first Chief Executive Officer. In this role, Ms. Autor will build on HIC's deep bench of cross-functional technical expertise, furthering the company's role as a sought-after advisor in both the private and public sectors. This press rele
- Nasdaq move will be effective on December 27, 2023 Amneal Pharmaceuticals, Inc. ("Amneal") (NYSE:AMRX) today announced that it will transfer its stock exchange listing to the Nasdaq Stock Market ("Nasdaq") from the New York Stock Exchange ("NYSE"). The Company expects the Nasdaq listing to occur on December 27, 2023 and will continue to trade under the current symbol "AMRX". Upon transferring, Amneal will become part of the Nasdaq Composite Index and Nasdaq Biotechnology Index. "We are pleased to join the community of global pharmaceutical companies listed on Nasdaq. We would also like to thank the NYSE for supporting the company over the last five years since our initial listing," sa
‒ Q3 2024 Net Revenue of $702 million; GAAP Net Loss of $0.2 million; Diluted Loss per Share of $0.00 ‒ ‒ Adjusted EBITDA of $158 million; Adjusted Diluted EPS of $0.16 ‒ ‒ Affirms 2024 Full Year Guidance ‒ Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company") today announced its results for the third quarter ended September 30, 2024. "Q3 was an excellent quarter where we continued to drive strong financial results across our diversified business and we announced three strategic actions to solidify our long-term growth. First, we launched CREXONT® for the treatment of Parkinson's disease. Second, we announced our collaboration with Metsera, Inc. to leverage Amneal's exp
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) announced today that the Company will release its third quarter 2024 financial results on Friday, November 8, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. The financial results and live webcast will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com. Individuals may register for the webcast by clicking the link here. To access the call through a conference line, dial 1 (833) 470-1428 (in the U.S.) or for a list of toll-free international numbers, visit this link. The access code for the call
‒ Q2 2024 Net Revenue of $702 million; GAAP Net Income of $6 million; Diluted Income per Share of $0.02 ‒ ‒ Adjusted EBITDA of $162 million; Adjusted Diluted EPS of $0.16 ‒ ‒ Raising 2024 Full Year Guidance ‒ ‒ CREXONT® U.S. FDA approval represents an exciting new long-term growth driver ‒ Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company") announced its results today for the second quarter ended June 30, 2024. "Amneal achieved strong revenues and adjusted EBITDA in the second quarter, and we are pleased to raise full year 2024 guidance driven by broad-based growth across our business. Amneal is a diversified and growing global pharmaceuticals company built on o
Potential first and only DHE autoinjector for tough-to-treat migraines and cluster headaches Exenatide approval highlights Amneal's capabilities in developing GLP-1 injectables Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), a global pharmaceutical company, today announced the advancement of two key strategic initiatives. First, the Company has resubmitted to the U.S. Food and Drug Administration (FDA) its new drug application (NDA) for dihydroergotamine (DHE) prefilled syringe autoinjector for the acute treatment of migraine with or without aura and cluster headache in adults. Second, Amneal has received approval from the FDA for exenatide, which is the Company'
‒ Q3 2024 Net Revenue of $702 million; GAAP Net Loss of $0.2 million; Diluted Loss per Share of $0.00 ‒ ‒ Adjusted EBITDA of $158 million; Adjusted Diluted EPS of $0.16 ‒ ‒ Affirms 2024 Full Year Guidance ‒ Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company") today announced its results for the third quarter ended September 30, 2024. "Q3 was an excellent quarter where we continued to drive strong financial results across our diversified business and we announced three strategic actions to solidify our long-term growth. First, we launched CREXONT® for the treatment of Parkinson's disease. Second, we announced our collaboration with Metsera, Inc. to leverage Amneal's exp
Pyridostigmine Bromide Extended Release is a once-daily soman nerve agent pretreatment pyridostigmine product for the U.S. Armed Services and U.S. allies developed utilizing Amneal's GRANDE® drug delivery technology Developed with the support of Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company"), a global pharmaceutical company based in the U.S., today announced that it has received U.S. Food and Drug Administration (FDA) approval of its New Drug Application (NDA) for Pyridostigmine Bromide Extended-Release (PB ER) Tablets USP 105 mg. PB ER 105 mg tablets are a once-
Builds on successful U.S. biosimilar partnership of 2 oncology products (RELEUKO® & FYLNETRA®)ADL018 is Kashiv's lead pipeline biosimilar program, currently in Phase IIIKashiv BioSciences, LLC ("Kashiv" or the "Company") today announced that it has entered into an exclusive licensing agreement for ADL018, a proposed biosimilar to omalizumab referencing XOLAIR®, with Amneal Pharmaceuticals, Inc. ("Amneal") for the United States.Omalizumab, which targets free IgE, is a humanized monoclonal antibody. It is an injectable prescription drug used to treat a number of chronic conditions such as severe persistent allergic asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), food allergies, and
https://www.reuters.com/legal/litigation/amneal-us-ftc-win-order-removing-teva-inhaler-patents-fda-list-2024-06-10/ Drugmaker Amneal Pharmaceuticals (AMRX.O), opens new tab with the backing of the U.S. Federal Trade Commission convinced a New Jersey federal court on Monday to remove five Teva Pharmaceutical (TEVA.TA), opens new tab patents from a U.S. Food and Drug Administration list of patents covering Teva's breathing drug ProAir HFA.U.S. District Judge Stanley Chesler agreed with Amneal and the FTC, opens new tab that Teva's patents only covered inhaler device technology, ordering it to remove the listings from the FDA's Orange Book and clearing an obstacle for Amneal's proposed generic.